deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04856189

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

A Phase Ib/II Study of Selinexor Plus Pembrolizumab in Cisplatin-Ineligible or Cisplatin-Refractory Patients With Advanced Urothelial Carcinoma

Sponsor: Karyopharm Therapeutics Inc

Conditions Advanced Urothelial Carcinoma Locally Advanced Urothelial Carcinoma Metastatic Urothelial Carcinoma Refractory Urothelial Carcinoma
Interventions Pembrolizumab Selinexor
Updated 8 times since 2021 Last updated: Jan 12, 2026 Started: Apr 8, 2021 Primary completion: Jan 4, 2024 Completion: Feb 13, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Poor accrual.

Other terminated trials from Karyopharm Therapeutics Inc

More terminations from Karyopharm Therapeutics Inc

Listed as NCT04856189, this PHASE1/PHASE2 trial focuses on Advanced Urothelial Carcinoma and Locally Advanced Urothelial Carcinoma and remains terminated or withdrawn. Sponsored by Karyopharm Therapeutics Inc, it has been updated 8 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~May 2021 – ~Jul 2022 · 14 months · monthly snapshotRecruiting~Jul 2022 – ~May 2023 · 10 months · monthly snapshotRecruiting~May 2023 – ~Aug 2023 · 3 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jul 2025 · 10 months · monthly snapshotRecruiting~Jul 2025 – ~Feb 2026 · 7 months · monthly snapshotUnknown~Feb 2026 – present · 5 months · monthly snapshotTerminated

Change History

8 versions recorded

  1. Feb 2026 — Present [monthly]

    Terminated PHASE1/PHASE2

    Status: Unknown → Terminated

  2. Jul 2025 — Feb 2026 [monthly]

    Unknown PHASE1/PHASE2

    Status: Recruiting → Unknown

  3. Sep 2024 — Jul 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Aug 2023 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 3 earlier versions

  1. May 2023 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  2. Jul 2022 — May 2023 [monthly]

    Recruiting PHASE1_PHASE2

  3. May 2021 — Jul 2022 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Karyopharm Therapeutics Inc
  • Mamta Parikh
  • National Cancer Institute (NCI)
Data source: University of California, Davis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations